Advances in genetic–immunological targeted therapies for psoriasis

IF 6.6 2区医学 Q1 IMMUNOLOGY

Current Opinion in Immunology Pub Date : 2025-04-30 DOI:10.1016/j.coi.2025.102559

Qi Zhen , Yirui Wang , Zhuo Li , Liangdan Sun

{"title":"Advances in genetic–immunological targeted therapies for psoriasis","authors":"Qi Zhen , Yirui Wang , Zhuo Li , Liangdan Sun","doi":"10.1016/j.coi.2025.102559","DOIUrl":null,"url":null,"abstract":"<div><div>Psoriasis is a common chronic immune-mediated inflammatory skin disease, with its pathogenesis involving genetic susceptibility, abnormal immune responses, and environmental factors. In recent years, targeted immunotherapy has become a prominent treatment approach. Various drugs targeting cytokines, such as interleukin-17, interleukin-23, and tumor necrosis factor-α, have been introduced, effectively alleviating symptoms. However, due to the complex immunopathogenesis of psoriasis and individual patient differences, single-target drugs may not consistently provide comprehensive treatment effects. Therefore, this article suggests that future research should prioritize multitarget combination therapies to enhance efficacy and reduce resistance. Personalized treatment strategies, based on patients’ genetic, immune, and clinical characteristics, should be developed. Investigating new immunomodulatory mechanisms and drugs, as well as combination therapies that integrate targeted drugs with phototherapy or cellular therapy, is also crucial. Additionally, exploring long-term efficacy and resistance mechanisms will help improve treatment outcomes, with the goal of transforming psoriasis treatment.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"94 ","pages":"Article 102559"},"PeriodicalIF":6.6000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0952791525000354","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Psoriasis is a common chronic immune-mediated inflammatory skin disease, with its pathogenesis involving genetic susceptibility, abnormal immune responses, and environmental factors. In recent years, targeted immunotherapy has become a prominent treatment approach. Various drugs targeting cytokines, such as interleukin-17, interleukin-23, and tumor necrosis factor-α, have been introduced, effectively alleviating symptoms. However, due to the complex immunopathogenesis of psoriasis and individual patient differences, single-target drugs may not consistently provide comprehensive treatment effects. Therefore, this article suggests that future research should prioritize multitarget combination therapies to enhance efficacy and reduce resistance. Personalized treatment strategies, based on patients’ genetic, immune, and clinical characteristics, should be developed. Investigating new immunomodulatory mechanisms and drugs, as well as combination therapies that integrate targeted drugs with phototherapy or cellular therapy, is also crucial. Additionally, exploring long-term efficacy and resistance mechanisms will help improve treatment outcomes, with the goal of transforming psoriasis treatment.

查看原文本刊更多论文

银屑病遗传免疫靶向治疗研究进展

银屑病是一种常见的慢性免疫介导的炎症性皮肤病，其发病机制涉及遗传易感性、免疫反应异常和环境因素。近年来，靶向免疫治疗已成为一种突出的治疗方法。各种针对细胞因子的药物，如白细胞介素-17、白细胞介素-23和肿瘤坏死因子-α，已被引入，有效缓解症状。然而，由于银屑病的免疫发病机制复杂且患者个体差异，单靶点药物可能无法始终如一地提供全面的治疗效果。因此，本文建议未来的研究应优先考虑多靶点联合治疗，以提高疗效，减少耐药。应根据患者的遗传、免疫和临床特点制定个性化的治疗策略。研究新的免疫调节机制和药物，以及将靶向药物与光疗或细胞疗法相结合的联合疗法也至关重要。此外，探索长期疗效和耐药机制将有助于改善治疗效果，以实现牛皮癣治疗的转变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Immunology 医学-免疫学

CiteScore

13.30

自引率

1.40%

发文量

审稿时长

67 days

期刊介绍： Current Opinion in Immunology aims to stimulate scientifically grounded, interdisciplinary, multi-scale debate and exchange of ideas. It contains polished, concise and timely reviews and opinions, with particular emphasis on those articles published in the past two years. In addition to describing recent trends, the authors are encouraged to give their subjective opinion of the topics discussed. In Current Opinion in Immunology we help the reader by providing in a systematic manner: 1. The views of experts on current advances in their field in a clear and readable form. 2. Evaluations of the most interesting papers, annotated by experts, from the great wealth of original publications. Current Opinion in Immunology will serve as an invaluable source of information for researchers, lecturers, teachers, professionals, policy makers and students. Current Opinion in Immunology builds on Elsevier''s reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health. It is a companion to the new Gold Open Access journal Current Research in Immunology and is part of the Current Opinion and Research(CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists'' workflow.